Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
In an attempt to overturn the largest award thus far to come out of the Risperdal mass tort program in Philadelphia, Janssen Pharmaceuticals has filed a list of alleged errors it contends that the trial court made during the A.Y. v. Janssen Pharmaceuticals case.
The October 12th filing contested the adequacy of the evidence on several points, charging that the court improperly limited Janssen’s ability to describe the benefits of Risperdal to the jury and challenging the $750,000 damages cap that the court applied to the case.
The case was the fifth lawsuit to be tried of the Risperdal mass tort program.
All the Risperdal cases make similar allegations, including charges that Janssen failed to properly warn that use of the drug caused male adolescent patients to grow female breasts (a condition known as gynecomastia), suffer psychological trauma, and in many cases required surgery to remove the breast tissue.
Risperdal is an anti-psychotic drug that was first approved by the FDA in 1993 to treat schizophrenia in adults.
The FDA later expanded approval of the drug to treat irritability in children and adolescents that were directly related to autism.
It has since also been approved to treat acute mania and bipolar disorders in younger patients.
Physicians have also commonly prescribed Risperdal off-label to treat other disorders among young patients, including attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).
As more young patients began taking Risperdal, concerns began to grow about the drug’s potential side effects, which for some patients can persist long after the drug is discontinued.
Risperdal lawsuits are being brought by males who claim that their prescription caused them to develop gynecomastia – enlarged breasts in men.
Since many of these young men are still not of legal age, the timing of the filing of these Risperdal lawsuits are not as strict and we anticipate that more of these lawsuits will continue to move through the courts.
While gynecomastia is not usually medically dangerous for young men, the psychological effects can be devastating.
A study published in the Plastic Reconstructive Surgery journal in 2013 concluded that gynecomastia has a significant psychosocial impact on adolescent patients that affects their self-esteem, mental health, and ability to function socially.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Consumers are advised that Melissa’s brand fresh organic basil in 2.0-ounce and 4.0-ounce packages are now included in a April 19, 2024 recall initiated by Miami, Florida-based Infinite Herbs LLC. The Melissa’s brand portion of the recall covers 96 2.0-ounce packages of fresh organic basil
Fresenius Kabi USA, LLC has announced a corrective Class I recall of an infusion pump software, LVP Software, that runs on the Ivenix Infusion System (IIS). Initiated by the firm on March 7, 2024, the action comes after multiple software anomalies were identified and found
According to the FDA, 20-ounce packages of “King Kullen Broccoli Cutlets with Bread Crumbs and Parmesan” have been recalled by New Haven, Connecticut-based Gracie’s Kitchen due to the potential presence of undeclared sesame and wheat. Individuals who live with allergies to either allergen are advised